As the designer and manufacturer of the prominent da Vinci surgical systems, Intuitive Surgical Inc. (NASDAQ: ISRG) is a leading name in robotic-assisted surgery. The company’s advanced platforms enable surgeons to perform minimally invasive procedures with enhanced precision and control, ultimately benefiting patients. For investors tracking the progress of technology and healthcare, Intuitive Surgical may be a standout.
Evaluating the company’s shares involves considering the ongoing adoption of robotic surgery, the expansion into new procedures, and the company’s innovation pipeline.
While we do not offer specific investment guidance, we can provide resources to support you. The latest Intuitive Surgical forecasts, earnings data, valuation metrics, and analysis from leading financial institutions are detailed below.
Intuitive Surgical Share Price & Chart
Between 2022 and 2025, the ISRG share price experienced significant growth, rising above the $600 per share mark.
P/E Ratio Average (End of 2024): 79.9
Intuitive Surgical does not pay a dividend.
Intuitive Surgical EPS and Revenue Breakdown 2020-2024
| Source: CompaniesMarketCap | Annual EPS | Annual Revenue |
|---|---|---|
| 2020 | $3.02 | $4.36 billion |
| 2021 | $4.79 | $5.71 billion |
| 2022 | $3.72 | $6.22 billion |
| 2023 | $5.11 | $7.12 billion |
| 2024 | $6.54 | $8.35 billion |
Intuitive Surgical is headquartered in Sunnyvale, California, US. The company, which has revolutionised the field of minimally invasive surgery, was founded in 1995. The company developed the da Vinci surgical system and first launched it in Europe in 1999, before it was cleared by the US Food and Drug Administration (FDA) in 2000. The da Vinci system allows surgeons to operate through small incisions using highly dexterous robotic instruments.
Intuitive Surgical’s core mission is to extend the benefits of minimally invasive surgery to more patients worldwide. The company’s revenue primarily derives from the sale of instruments and accessories used in procedures, as well as from service contracts for its installed base of da Vinci systems. Beyond the da Vinci platform, Intuitive also offers the Ion endoluminal system for minimally invasive lung biopsy. Intuitive Surgical’s stock trades on the Nasdaq exchange under the ticker symbol ISRG. T
Intuitive Surgical Stock Forecast
Data compiled by TradingView shows that of the 34 analysts covering the stock, 20 have a “Buy” rating, 12 have a “Hold” rating, and 2 have a “Sell” rating.
A View From the Bulls: When it comes to the bullish argument for ISRG, analysts at Barclays said in a recent note that the stock’s pullback represents an “attractive” buying opportunity. The bank believes that concerns regarding the risk of reprocessed instruments in 2027 and beyond are overblown. Barclays analysts explained that reprocessed and remanufactured instruments are available for various indications, but they usually lag recent innovations and come with trade-offs. The firm reiterated an Overweight rating and $635 price target on the stock.
A View From the Bears: However,Deutsche Bank has taken the opposite view. It recently downgraded Intuitive Surgical to Sell from Hold with a price target of $440, stating that encroachment on ISRG’s Instruments and Accessories segment by remanufactured instruments is inevitable. They believe it will likely be increasingly meaningful over the next few years. The bank predicts a growing number of Intuitive’s customers will explore the adoption of remanufactured instruments, given the potentially substantial profitability gains. Deutsche Bank’s view is based on its discussions with multiple robotic surgery programs.
The bank estimates that 46% of Intuitive’s US I&A revenues could be at risk of encroachment by third-party-remanufactured devices. Its model predicts no material impact in 2026, but it forecasts steadily increasing headwinds in 2027 and especially in 2028.
Average Analyst Consensus 12-Month Price Target: $579.51
Our View: Intuitive Surgical maintains a strong position, thanks to its technology and deep integration into surgical workflows, which provide significant advantages. However, competition is increasing, and investors should carefully monitor the risk highlighted by Deutsche Bank above.
Who Should Buy Intuitive Surgical Shares
Intuitive Surgical shares typically appeal to investors seeking exposure to companies operating in the medical robotics space.
The stock is attractive to individuals looking for a company with a strong competitive moat. However, they should also have faith in the company’s ability to overcome the current headwinds from competition.
It may also be a suitable investment option for those who believe in the growing adoption of robotic platforms in various surgical specialties.
Furthermore, those valuing a company with a strong recurring revenue stream might find Intuitive Surgical an appealing option.
